Hiroki Narita
Directeur/Bestuurslid bij Cardio, Inc.
Profiel
Hiroki Narita is currently the Director at Cardio, Inc. and the Senior Managing Director at Daiwa Corporate Investment Co., Ltd.
He previously held positions as an Outside Director at REGiMMUNE Corp., an Outside Director at TMRC Co. Ltd., a Director at Ribomic, Inc., an Outside Director at RaQualia Pharma, Inc., and a Deputy General Manager at Daiwa SMBC Capital Co., Ltd.
Mr. Narita completed his undergraduate degree at Aoyama Gakuin University.
Actieve functies van Hiroki Narita
Bedrijven | Functie | Begin |
---|---|---|
Cardio, Inc. | Directeur/Bestuurslid | 15-07-2009 |
Daiwa Corporate Investment Co., Ltd.
Daiwa Corporate Investment Co., Ltd. Investment ManagersFinance Daiwa Corporate Investment Co. Ltd. (Daiwa Corporate Investment) is a private equity arm of Daiwa Securities Group Inc. and is headquartered in Tokyo, Japan. The firm was founded in 1982. | Private Equity Investor | 01-04-2022 |
Eerdere bekende functies van Hiroki Narita
Bedrijven | Functie | Einde |
---|---|---|
RAQUALIA PHARMA INC. | Directeur/Bestuurslid | 31-10-2011 |
TMRC Co. Ltd.
TMRC Co. Ltd. Medical/Nursing ServicesHealth Services TMRC Co. Ltd. provides contract research and manufactures medicines. It develops anti-cancer products and those for cancer associated disorders. The company was founded by Hisao Ekimoto in January 2002 and is headquartered in Tokyo, Japan. | Directeur/Bestuurslid | - |
Daiwa SMBC Capital Co., Ltd.
Daiwa SMBC Capital Co., Ltd. Investment ManagersFinance The Group's principal activity is the venture capital operation and financing. The operations are carried out through the following divisions: Investment division deals with investment in venture business of domestic and overseas companies; establishing, operation and management of assets of investment partnerships and Financing division deals with loans, leasing, and other financial services. | Corporate Officer/Principal | - |
RIBOMIC INC. | Directeur/Bestuurslid | - |
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Directeur/Bestuurslid | - |
Opleiding van Hiroki Narita
Aoyama Gakuin University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
RIBOMIC INC. | Health Technology |
RAQUALIA PHARMA INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Daiwa SMBC Capital Co., Ltd.
Daiwa SMBC Capital Co., Ltd. Investment ManagersFinance The Group's principal activity is the venture capital operation and financing. The operations are carried out through the following divisions: Investment division deals with investment in venture business of domestic and overseas companies; establishing, operation and management of assets of investment partnerships and Financing division deals with loans, leasing, and other financial services. | Finance |
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
TMRC Co. Ltd.
TMRC Co. Ltd. Medical/Nursing ServicesHealth Services TMRC Co. Ltd. provides contract research and manufactures medicines. It develops anti-cancer products and those for cancer associated disorders. The company was founded by Hisao Ekimoto in January 2002 and is headquartered in Tokyo, Japan. | Health Services |
Cardio, Inc. | |
Daiwa Corporate Investment Co., Ltd.
Daiwa Corporate Investment Co., Ltd. Investment ManagersFinance Daiwa Corporate Investment Co. Ltd. (Daiwa Corporate Investment) is a private equity arm of Daiwa Securities Group Inc. and is headquartered in Tokyo, Japan. The firm was founded in 1982. | Finance |